Transgenic Group Inc. (TYO:2342)
256.00
+5.00 (1.99%)
Aug 27, 2026, 3:30 PM JST
Transgenic Group Revenue
Transgenic Group had revenue of 3.66B JPY in the quarter ending June 30, 2026, with 14.45% growth. This brings the company's revenue in the last twelve months to 13.64B, up 2.37% year-over-year. In the fiscal year ending March 31, 2026, Transgenic Group had annual revenue of 13.17B with 1.30% growth.
Revenue (ttm)
13.64B
Revenue Growth
+2.37%
P/S Ratio
0.31
Revenue / Employee
60.07M
Employees
227
Market Cap
4.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.17B | 169.00M | 1.30% |
| Mar 31, 2025 | 13.01B | -78.00M | -0.60% |
| Mar 31, 2024 | 13.08B | 1.65B | 14.47% |
| Mar 31, 2023 | 11.43B | -1.15B | -9.12% |
| Mar 31, 2022 | 12.58B | 1.53B | 13.85% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kohjin Bio | 4.69B |
| Soiken Holdings | 3.87B |
| Human Metabolome Technologies | 1.42B |
| PRISM BioLab Co.,LTD | 737.27M |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| Ribomic | 7.50M |